Rapid Micro Biosystems (RPID) Income from Continuing Operations (2020 - 2026)
Rapid Micro Biosystems (RPID) reported Income from Continuing Operations of 14275000.0 for Q1 2026, down 26.74% on a YoY basis from 19486041.09 in Q1 2025, and down 14.23% sequentially from 12497000.0 in Q4 2025.
Rapid Micro Biosystems (RPID) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Rapid Micro Biosystems (RPID) has 7 years of Income from Continuing Operations data on file, last reported at 14275000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 26.74% year-over-year to 14275000.0; the trailing twelve-month figure through Mar 2026 stood at 50135000.0 (down 11.83% YoY), and the FY2025 full-year result was 47123000.0, changed 0.5% from the prior year.
- Income from Continuing Operations eased to 14275000.0 in Q1 2026, from 12497000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 9666000.0 in Q4 2024 to a low of 16464000.0 in Q4 2022.
- A 5-year average of 13034705.88 and a median of 13103000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations jumped 34.61% in 2022 and retreated 29.29% in 2025, its largest moves.
- Tracing RPID's Income from Continuing Operations over 5 years: stood at 16464000.0 in 2022, then jumped by 32.14% to 11172000.0 in 2023, then climbed by 13.48% to 9666000.0 in 2024, then fell by 29.29% to 12497000.0 in 2025, then fell by 14.23% to 14275000.0 in 2026.
- Business Quant data shows RPID's Income from Continuing Operations at 14275000.0 in Q1 2026, 12497000.0 in Q4 2025, and 11505000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Rapid Micro Biosystems | 90.41 Mn | 80.98 Mn | 371,000.00 | -14.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.28 Mn |
| Dec 31, 2025 | -12.50 Mn |
| Sep 30, 2025 | -11.51 Mn |
| Jun 30, 2025 | -11.86 Mn |
| Mar 31, 2025 | -11.26 Mn |
| Dec 31, 2024 | -9.67 Mn |
| Sep 30, 2024 | -11.32 Mn |
| Jun 30, 2024 | -12.58 Mn |
| Mar 31, 2024 | -13.32 Mn |
| Dec 31, 2023 | -11.17 Mn |
| Sep 30, 2023 | -13.39 Mn |
| Jun 30, 2023 | -14.02 Mn |
| Mar 31, 2023 | -13.89 Mn |
| Dec 31, 2022 | -16.46 Mn |
| Sep 30, 2022 | -16.34 Mn |
| Jun 30, 2022 | -13.10 Mn |
| Mar 31, 2022 | -14.93 Mn |
| Dec 31, 2021 | -14.61 Mn |
| Sep 30, 2021 | -24.99 Mn |
| Jun 30, 2021 | -11.83 Mn |